Security Type: Common Stock
Bid 48.00
Bid Size 1
Ask 77.50
Ask Size 1
Open 64.43
Day High 65.40
Day Low 64.05
Previous Close 64.78
52-Week High 86.582
52-Week Low 43.27
Price Performance (Last 52 Weeks)+34.43%
Held by ETPs
Yes (97)
Volume 0
90-Day Average Volume 1,191,944
Primary Exchange NASDAQ-NMS
Index Not In
S&P 500®
DJIA®
NASDAQ 100®
Options
Yes

Detailed Quote

Note: You can save only one view at the time. Saving this view will overwrite your previously saved view.

Please use the Advanced Chart if you want to have more than one view.

Cancel 
Save View
Your view has been saved
Failed
Your view hasn't been saved
TODAY 2D 5D 10D 1M 3M 6M YTD 1Y 3Y 5Y 10Y
DELAYED DATA AS OF
Text Note
Chart Settings
Show/Hide


Please note you can display only one indicator at a time in this view. Please use Advanced Chart if you want to display more than one.

Attention

Please note you can display only one indicator at a time in this view. Please use Advanced Chart if you want to display more than one.

Don't show again

News & Events

Log in for more news
  • Show article details.

    Positive preliminary results from ATL1102 for DMD Phase II trial

    PR Newswire – 09/17/2019

    MELBOURNE, Australia, Sept. 17, 2019  Antisense Therapeutics (ATHJF) is pleased to advise that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy therapy, is indicative of a positive drug effect of ATL1102 at the dose tested both at an immunomodulatory ...

  • Show article details.

    Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

    GlobeNewswire – 09/16/2019

    Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients with all forms of TTR amyloidosis BOSTON and CARLSBAD, Calif., Sept. 16, 2019 --  Akcea Therapeutics (AKCA), Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), and Ionis Pharmaceuticals (IONS), In...

  • Show article details.

    Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

    GlobeNewswire – 08/29/2019

    Multiple presentations on the long-term efficacy and safety of TEGSEDI® in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of AKCEA-TTR-LRx for the treatment of Transthyretin Amyloidosis BOSTON and CARLSBAD, Calif., Aug. 29, 2019 -- Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), and Ionis Pharmaceutic...

  • Show article details.

    Ionis Pharmaceuticals to present at upcoming investor conferences

    PR Newswire – 08/28/2019

    CARLSBAD, Calif. The above listed dates are subject to change. A live webcast of the presentations will be available on the Investors & Media section of the Ionis website.

  • Show article details.

    BRIEF-Ionis Licenses Hepatitis B Program To GSK

    Reuters – 08/27/2019

    Ionis Pharmaceuticals Inc (IONS): * IONIS LICENSES HEPATITIS B PROGRAM TO GSK. * Ionis Pharmaceuticals Inc (IONS) - GSK EXERCISES OPTION TO LICENSE PROGRAM FOLLOWING POSITIVE PHASE 2 RESULTS. * Ionis Pharmaceuticals Inc (IONS) - UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE LICENSE FEES, MILESTONE PAYMENTS UP TO $262 MILLION, INCLUDING $25 MILLION LICENSE FEE.

Events

  • Nov
    04

    IONS to announce Q3 earnings (Unconfirmed)

More News & Events

Company Profile

Log in for more information

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of…

View more

Sector (GICS®)

Health Care

Industry (GICS®)

Biotechnology

Environmental, Social & Governance Summary (ESG)

  Secure. Log in required.

ESG ratings enable you to leverage independent ESG research to evaluate how companies are managing ESG risks and addressing ESG opportunities. Learn more

To access the latest ESG Research, Visit the new Stock Dashboard

About Environmental, Social & Governance Summary (ESG)

MSCI ESG Ratings

Environmental, Social, and Governance (ESG) Flags: MSCI Ratings publishes Environmental, Social and Governance (ESG) ratings on over 6,000 companies worldwide. These ratings provide an independent assessment of the sustainable investment value of public companies. The ESG Ratings model is based on a carefully crafted and applied list of KeyMetrics® that result in an overall ESG concern level as expressed by Red (High Concern), Yellow (Average Concern), and Green (Low Concern) flags. Unlike traditional ESG risk models, MSCI's rating methodology is designed to identify risks most likely to affect equity valuations. Specifically, these ratings reflect actual corporate behaviors rather than policies or affirmations of intent to adhere to best ESG practices. Further, unlike other models with evenly weighted metrics, we assign context-sensitive relative weightings to our key metrics, based on market, regional, ownership or sector differences. Individual company scores are then assigned as a percentile rank, ranging from 1 (worst ranked) to 100 (best) on the basis of these KeyMetrics® and then converted to the Red, Yellow or Green flag designation.

Company Reports: In addition to a company's overall risk rating, ESG reports also include an industry rating based on a comparison between the company's risk levels in each ESG component area relative to its industry peers. Further, the ESG analysis serves as a summary of behavioral events that contributed to the company's overall risk level.

More About MSCI

Full Time Employees: 737

Executives  Secure. Log in required.

www.ionispharma.com

2855 Gazelle Court
Carlsbad, CA 92010
United States of America

1-760-931-9200

Analyst Opinions

The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....

Log in to view the Equity Summary Score for IONS

Research Reports

Company Research Highlights® Report (PDF) Requires Login.

This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.

Compustat ® Company Report Requires Login.

This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.

*Generated reports are built dynamically when you select them. Reports may not be available for some symbols. Select the link to check availability for this symbol.

IONS Industry Comparison:

IONSIndustry AveragePercentile
in Industry
Market Capitalization$9.10B$12.70B98th
Total Return (1 Year Annualized)
 
+34.43%+1.60%89th
Beta0.801.3367th
EPS (TTM)
 
$2.79$4.4398th
Current Consensus EPS Estimate------
EPS Growth
(TTM vs. Prior TTM)
--+84.01%--
P/E (TTM)
23.34192.7664th
Dividend Yield (Annualized)------
Total Revenue (TTM)
$798.54M$11.41B96th
Revenue Growth
(TTM vs Prior TTM)
+45.65%+60.45%69th
Shares Outstanding140,500,000490,102,14488th
Institutional Ownership89.06%76.17%90th
† The Equity Summary Score provided by Thomson Reuters StarMine is current as of the date specified. There may be differences between the Equity Summary Score analyst count and the number of underlying analysts listed. Due to the timing in receiving ratings changes into the Equity Summary Score model, the Equity Summary Score analyst count may lag the ratings count displayed by one or more days. There may also be analyst count variations for symbols with multiple share classes and ADRs. More details on Equity Summary Score calculation are included in the Understanding and Using the Equity Summary Score Methodology (PDF).

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

455221.19
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.